Sono TEK (SOTK) Q2 FY27 earnings call: guidance and Q&A

Does the company's success with integrated production line orders create a 'flywheel effect' for repeat business, and how does this impact the outlook?

Management confirmed that integrated orders create a flywheel effect, where successful process development leads to high-volume manufacturing and additional orders as customers expand. The recent $7.2 million order is a prime example, as the customer continues to expand production lines, Sono-Tek remains their coating expert, leading to continuous orders.

“That's exactly right. And this last order that we just announced for $7.2 million is really a prime example of that. You know, that's a customer that we walked through in the R&D phase very successfully and in the pilot line phase. And then we developed, you know, a really sophisticated high-volume production system for them. And that sold well, but it doesn't end there.”

asked by William Nicklin · answered by R. Harshbarger

Given the success of the FDE team, what are the plans for its expansion in the next 12-18 months, and what does this indicate about business momentum?

Management stated that the FDE team, currently at four people (three engineers, one project manager), has proven its model and will continue to expand, potentially doubling in size within one to two years. This expansion is driven by strong customer demand and the quick return on investment compared to traditional R&D.

“I wouldn't be surprised to see that team doubled in another year or two, maybe even quicker. You know, the challenge for us there is mostly that these are really skilled, experienced people with our technology and how to do integration.”

asked by William Nicklin · answered by R. Harshbarger

Are there additional opportunities in medical balloons or other medical device applications beyond the current success areas, such as implants?

The medical market is rapidly evolving, with Sono-Tek now considered a medical device implantable company with high-volume production capabilities. Many companies making drug-eluting balloons and stents also make other devices like heart valves or diabetes devices that require thin film coatings. Sono-Tek's proven success and financial stability are attracting new customers for next-gen medical devices, which are currently being proven in their labs.

“So many of these devices now need thin film coatings onto them to prove some sort of functionality. And Sono-Tek is no longer now being considered, say, a stent coating company. Now we're being considered a medical device implantable company and one that has the capabilities for high volume production.”

asked by Edward Jackson · answered by R. Harshbarger

What is the current manufacturing capacity, how long will it last, and what are the plans for future expansion?

Sono-Tek plans a major expansion starting late calendar year, building a mezzanine structure to increase capacity from $27 million to $33-$36 million. A subsequent retrofit of an unoccupied building will take capacity to $44-$45 million. Due to increasing large orders, planning has begun for a further expansion to $85 million, which may involve considering locations outside New York State for incentives.

“Yes, we are intending to start a major what we consider a major expansion at the end of this current calendar year, be like December, maybe January, we'll start actually making things happen there. I actually have a meeting tomorrow on this because it's with these latest orders it's kind of accelerated things to get things going quicker.”

asked by Edward Jackson · answered by R. Harshbarger

Given the elevated gross margins, how much is attributable to selling mix versus structural advantages with higher ASP machines, and are current levels sustainable?

The elevated gross margins are due to both selling mix and structural advantages. High ASP production machines, especially repeat orders, drive higher margins because customers pay for increased value and costs are optimized after the first machine. The company is cautiously optimistic that what is currently 'unusually favorable' will become the norm as more high ASP, high-volume repeat orders enter the backlog, particularly with onshoring trends reducing distributor discounts.

“But what is exciting is what's flowing into our backlog is, again, more of these high ASP, high volume production systems. So what is we're describing as unusually favorable right now, I'm optimistically hoping that we take that unusual away as things go forward and we start to get more and more of orders that look like those orders where it won't become unusual anymore.”

asked by Sam Dufault · answered by R. Harshbarger

What is the specific opportunity in semiconductors beyond photoresist, and how quickly can these opportunities translate into significant revenue?

The semiconductor opportunity is broader than photoresist, with inquiries for unique thin film processes on next-gen AI chips. Sono-Tek is focusing on scaling offerings for 200mm and 300mm wafers. While lab-proven processes can move quickly, actual implementation in fabs tends to be slower. Significant impact (e.g., 10-machine orders) might be 1-3 years out, but initial machine placements for new processes could occur within a year. The company's proven high-volume production capabilities are now attracting interest from semiconductor firms.

“But I firmly believe there will be more applications outside of photoresist as well that may actually even pull us there into the larger 300 millimeter area, maybe even faster than the planned photoresist area. There's a lot of unique thin film processes that take place in that whole semiconductor manufacturing area.”

asked by Jason Erasner · answered by R. Harshbarger